NASDAQ: UTHRUnited Therapeutics Corporation

HealthcareMkt Cap $23.64BCongress ownership rank #511

United Therapeutics Corporation Congressional Trading

According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 48 trades in United Therapeutics Corporation (NASDAQ: UTHR) since 2015, across 5 members, worth an estimated $2.8M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 27 buys against 21 sells, a modestly buy-led skew, with Democratic members responsible for 6% of the trades and Republican members 94%. The most recent disclosure shown was filed November 2025, and Lisa Mcclain has filed the most UTHR transactions among those shown, with 4. Other recent filers include Michael T. McCaul. One notable disclosed move was a purchase by Lisa Mcclain on June 11, 2025, up 98.7% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the United Therapeutics Corporation (UTHR) stock overview and the complete trade table below.